Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement (Q28175558)

American Journal of Medicine

Europe PubMed Central

title

Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement (English)

0 references

author name string

C J Hawkey

series ordinal

1

0 references

A I Lanas

series ordinal

2

0 references

language of work or name

English

0 references

publication date

8 January 2001

0 references

published in

0 references

volume

110

0 references

page(s)

79S-100S

0 references

issue

1A

0 references

cites work

The use of consensus to develop guidelines for the management of Helicobacter pylori infection in primary care. European Society for Primary Care Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

An evidence-based appraisal of reflux disease management--the Genval Workshop Report

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Postoperative analgesia with i.v. propacetamol and ketoprofen combination after disc surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Treating acute pain in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Dr

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Ibuprofen versus other non-steroidal anti-inflammatory drugs: use in general practice and patient perception

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Naproxen and paracetamol compared with naproxen only in coxarthrosis. Increased effect of the combination in 18 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Additive effect of combined naproxen and paracetamol in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

n of 1 trials in osteoarthritis. Study was conceptually and statistically biased

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

An endoscopic comparison of gastroduodenal injury with over-the-counter doses of ketoprofen and acetaminophen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effect of acetaminophen on human gastric mucosal injury caused by ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Smoking, nonsteroidal anti-inflammatory drugs, and acetaminophen in gastric ulcer. A study of associations and of the effects of previous diagnosis on exposure patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin, paracetamol, and haematemesis and melaena

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The comparative effects of paracetamol and indomethacin on renal function in healthy female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effects of non-steroidal anti-inflammatory drugs and prednisolone on synovial fluid white cells, prostaglandin E2, leukotriene B4 and cyclic AMP in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin use and reduced risk of fatal colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal antiinflammatory drugs and colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Colorectal cancer and nonsteroidal anti-inflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?: The Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk of Alzheimer's disease and duration of NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Prescribing of nonsteroidal anti-inflammatory drugs in general practice: determinants and consequences.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The iatrogenic cost of non-steroidal anti-inflammatory drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Overall mortality among patients surviving an episode of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Emergency admissions for upper gastrointestinal disease and their relation to NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Recent considerations in nonsteroidal anti-inflammatory drug gastropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Non-steroidal anti-inflammatory drugs and peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk factors associated with refractory peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

1 reference

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The cyclooxygenase-2 inhibitors: safety and effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study☆, ☆☆

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Associations between maternal decaffeinated and caffeinated coffee consumption and fetal growth and gestational duration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

1 reference

7 January 2021

Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Decisions loom on selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Renal side-effects of cyclo-oxygenase-type-2 inhibitor use

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Are selective COX-2 inhibitors nephrotoxic?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Angiotensin II attenuates renal cortical cyclooxygenase-2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Silent peptic ulceration: deadly silence or golden silence?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Platelet-active drugs: the relationships among dose, effectiveness, and side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Adverse effects of low-dose aspirin in a healthy elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Evidence of aspirin use in both upper and lower gastrointestinal perforation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin: new cardiovascular uses for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin use and the risk for colorectal cancer and adenoma in male health professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin and the Risk of Colorectal Cancer in Women

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin use and chronic diseases: a cohort study of the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin use and lung, colon, and breast cancer incidence in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Aspirin use, cancer, and polyps of the large bowel

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Histamine H2 blocking drugs and the risk for Alzheimer's disease: the Rotterdam Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021

Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900651-3

7 January 2021